In focus · trending topic

Dr. David Strayer

1 stories · following the connections

Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen® Phase III Trial in Patients with CFS/ME

By Nasdaq OMXOct 31, 2016, 12:31 PM UTC